Home Infusion Therapy Market Size, Share, Growth Drivers, Industry Analysis and Forecast 2026–2034

Ajit Kumar

2 hours ago

5 min read

Home Infusion Therapy Market Overview Analysis By Fortune Business Insights Analysis

Market Size & Growth Outlook

According to Fortune Business Insights: The global home infusion therapy market was valued at USD 42.44 billion in 2025 and is projected to grow from USD 45.67 billion in 2026 to USD 128.91 billion by 2034, exhibiting a CAGR of 13.85% during the forecast period. North America dominated the market with a 41.20% share in 2025.

Home infusion therapy is a process in which patients receive biologics and drugs at home. It also includes nursing services that provide, train, and educate patients on the safe intravenous administration of drugs. Receiving care at home rather than in a healthcare facility has become a cost-effective option for patients and has reduced hospital costs, which boosts demand for the therapy. Government programs are encouraging the shift to home care to reduce overall hospitalization and treatment costs. Growing patient preference for home care, particularly for infusion treatment, and developments in infusion devices designed for home use are also expected to fuel the market. According to the Research Institute for Home Care's 2023 Home Care Chartbook, there were 11,353 active home health agencies in the U.S. in 2022.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/102989

Market Trends

Shift Toward Home Medical Care: Patients and providers are increasingly treating non-critical conditions in outpatient settings, including the home. Private and for-profit companies have entered the sector and are training medical personnel to deliver infusion therapy at home. Patient preference is expected to grow, owing to convenience and new therapies that can be administered safely and cost-effectively at home. Wearables, point-of-care technology, and telemedicine are improving remote monitoring and enabling safer care at home.

Comparative studies show substantial cost reductions for specialty infusion drugs at home versus hospital settings. According to various studies, the cost of IVIG infusion at Accredo in the home setting is 62% lower than medical office administration and 87% lower than hospital outpatient administration, which has drawn many patients to home treatment.

Growth Factors

Rising Chronic Disease Prevalence and Geriatric Population: The burden of chronic disease is increasing globally, including immune deficiencies, cancer, diabetes, and congestive heart failure. According to the WHO, chronic diseases affect approximately 133 million Americans, or 40% of the population. The growing geriatric population is more prone to chronic disease and prefers home treatment. A survey by the American Association of Retired People found that most older adults prefer to remain in their own homes as long as possible, and Dartmouth Atlas researchers found that more than 80% of U.S. patients want to avoid hospitalization and intensive care in the terminal phase of life.

Demand for Home Care Intravenous Drug Infusion: Hospital-acquired infections are a major safety concern. According to the CDC, an estimated 1.7 million patients in the U.S. contract a hospital-acquired infection every year. Immunocompromised patients receiving infusion in hospitals face greater risk, which makes the home a safer alternative and strengthens patient preference for home infusion.

Restraining Factors

Limited Reimbursement for Home Care: Reimbursement policies are absent in many developing nations, and reimbursement rates vary by therapy and indication. Out-of-pocket healthcare spending is higher in emerging nations such as India and China than in countries with established reimbursement structures. Together with a limited number of public and private home infusion providers, a lack of trained medical personnel, and other resource constraints, this is expected to limit adoption of these services in emerging countries.

Segmentation Analysis

By Product: Drugs are expected to hold a dominant 77.54% share in 2026. Growth is supported by rising cancer incidence, other chronic and acute conditions, and a strong drug pipeline, along with supportive regulators and increasing product approvals. The U.S. FDA approved more than 100 injectable drugs from 2016 to 2022. Services are expected to see significant growth on the rise in healthcare professionals and the services offered by global and domestic players. Devices are expected to see the second-highest growth after services, owing to new entrants and innovations in medication delivery systems.

By Indication: Anti-infective led with a 25.52% share in 2026 on the higher prevalence of infectious diseases, ease of set-up, and low cost of the therapy. Chemotherapy is estimated to grow the fastest, driven by the rise in cancer prevalence and awareness of the benefits of receiving chemotherapy at home. According to the American Cancer Society, an estimated 1.8 million new cancer cases were registered in the U.S. in 2020. Immunoglobulin therapy is estimated to see strong growth on the rise in primary immunodeficiency diseases and new SCIG product approvals. Hydration therapy, enteral nutrition, total parenteral nutrition, and others complete the segmentation.

Regional Outlook

North America reached USD 17.49 billion in 2025, representing 41.20% of revenue, and is projected to reach USD 18.69 billion in 2026. According to a 2019 Becker's Healthcare report, around 3 million patients in the U.S. received home infusions for various indications, a 300% increase over the prior decade. The U.S. market is projected to reach USD 18.19 billion by 2026.

Europe contributed approximately USD 13.69 billion in 2025 (32.26% share) and is expected to reach USD 14.77 billion in 2026, supported by the rising geriatric population, chronic disease burden, and government and company initiatives. In January 2021, Eitan Medical launched a U.K. operation to better support Sapphire infusion pump customers, including NHS trusts, private hospitals, and home-care providers. The U.K. is projected at USD 1.92 billion by 2026 and Germany at USD 3.09 billion.

Asia Pacific stood at USD 8.07 billion in 2025 (19.00% share) and is projected to reach USD 8.81 billion in 2026. It is projected to register the highest CAGR, driven by awareness of the treatment, adoption of innovative technologies, and rising cancer and diabetes prevalence. Japan is projected at USD 1.51 billion by 2026, China at USD 3.02 billion, and India at USD 1.34 billion.

Rest of the World reached USD 3.19 billion in 2025 (7.53% share) and is expected to reach USD 3.40 billion in 2026. The market is nascent, but growing awareness and a gradual shift toward home care are expected to support growth.

Competitive Landscape

The market is consolidated, with a few players such as B. Braun Melsungen AG, Optum, Inc., Option Care Health Inc., and Baxter. These companies focus on innovative infusion pumps and on expanding their geographic footprint. In 2020, key players reported significant revenue growth from home infusion services as more patients received infusion therapy at home during COVID-19 restrictions. Option Care Health's revenue increased 30.1% in 2020 to USD 3,302.6 million. Smaller manufacturers are emphasizing expansion in developing nations with delivery devices and supplies for home care.

Companies profiled include Option Care Health Inc. (U.S.), Optum, Inc. (U.S.), CareCentrix, Inc. (U.S.), CVS Health (U.S.), KabaFusion (U.S.), PromptCare (U.S.), Baxter International Inc. (U.S.), and Infusystem (U.S.).

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/102989

Key Industry Developments

January 2024: BrightStar Care collaborated with Paragon Healthcare to offer home infusion services in the U.S.

August 2023: NeuroNet Pro and WeInfuse collaborated to offer workflow solutions for infusion therapy in neurology practices.

June 2023: Yale New Haven Health and CarepathRx announced a partnership for home infusion services.

March 2021: PromptCare acquired NBN Infusions, Inc., a New Jersey-based home infusion and respiratory therapy provider, reinforcing its share in the Northeastern U.S.

January 2021: CVS Health collaborated with the Cancer Treatment Centers of America to increase access to chemotherapy at home for eligible patients.

February 2020: Avoset developed AvosetGO, a homecare infusion pump with an embedded touch screen that can be monitored via smart devices.

What Everyone Should Know About Japan’s Market Home Infusion Therapy Market Insights